Hepatology

Article	Citations
Epidemiology of Hepatocellular Carcinoma	1128
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review	749
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	677
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	605
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD	498
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	388
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases	345
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	330
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma	328
From NAFLD to MAFLD: Implications of a Premature Change in Terminology	269
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study	262
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future	223
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis	220
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade	215
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma	210
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial	207
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network	193
Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides	178
Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression	175
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH	172
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis	172
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC	171
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma	160
Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study	144
Liver Biochemistries in Hospitalized Patients With COVID‐19	142

High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population	142
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder	142
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases	138
Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis	138
Immune‐Responsive Gene 1/Itaconate Activates Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocytes to Protect Against Liver Ischemia–Reperfusion Injury	136
Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement	134
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	132
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH	123
Emerging immunotherapy for HCC: A guide for hepatologists	122
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	121
N6‐Methyladenosine Reader Protein YT521‐B Homology Domain‐Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes	121
The Tumor Microenvironment in Cholangiocarcinoma Progression	116
Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis	114
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease	114
Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling	114
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD	113
Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis	112
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	111
A Circular RNA, Cholangiocarcinoma‐Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers	110
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases	109
Biomarkers for Hepatobiliary Cancers	107
Surgical Treatments of Hepatobiliary Cancers	106
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy	106
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma	105
Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children	105
SIRT1 Regulates N6‐Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2‐Dependent FTO SUMOylation	104
Global burden of NAFLD and chronic liver disease among adolescents and young adults	102
HBV‐Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC	100
Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice	97
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study	97
Osteopontin Takes Center Stage in Chronic Liver Disease	97
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma	96
Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis	96
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?	96
Endoplasmic reticulum stress in liver diseases	95
NAFLD: Reporting Histologic Findings in Clinical Practice	95
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	95
PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis	94
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis	94
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1	93
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC	93
Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells	90
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	90
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	89
A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD	88
Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease	88
Perioperative Presentation of COVID‐19 Disease in a Liver Transplant Recipient	88
NAFLD‐related hepatocellular carcinoma: The growing challenge	88
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis	88
Intestinal Virome in Patients With Alcoholic Hepatitis	88

AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis	87
Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH	87
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma	86
Getting to HBV cure: The promising paths forward	86
Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies	86
Hypoxia‐Inducible Exosomes Facilitate Liver‐Tropic Premetastatic Niche in Colorectal Cancer	84
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection	84
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	80
Reply: A multisociety Delphi consensus statement on new fatty liver disease nomenclature	80
Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA	80
Heterogeneity of HSCs in a Mouse Model of NASH	80
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation	80
The Use of Rifaximin in Patients With Cirrhosis	79
Local and Regional Therapies for Hepatocellular Carcinoma	79
Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases	78
Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action	76
An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States	75
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease	75
Effect of increased alcohol consumption during COVID‐19 pandemic on alcohol‐associated liver disease: A modeling study	74
A revised electronic version of RUCAM for the diagnosis of DILI	72
Regional Differences in Human Biliary Tissues and Corresponding In Vitro–Derived Organoids	72
Immunotherapy as a Downstaging Therapy for Liver Transplantation	70
Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6‐Methyladenosine mRNA Methylation‐Dependent Mechanism	70
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria	70
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases	70
The IKKβ‐USP30‐ACLY Axis Controls Lipogenesis and Tumorigenesis	69
Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer	69
Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury	68
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease	68
Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis	68
Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study	68
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	67
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome	67
Liver zonation, revisited	67
Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators	67
Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐Year Experience in 207‐Patient Cohort	66
Machine perfusion in liver transplantation	66
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH	65
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer	65
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis	65
Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory Syndrome in Children: A Single‐Center Report	65
Hydrogen Sulfide Alleviates Liver Injury Through the S‐Sulfhydrated‐Kelch‐Like ECH‐Associated Protein 1/Nuclear Erythroid 2–Related Factor 2/Low‐Density Lipoprotein Receptor–Related Protein 1 Pathway	64
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC	64
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study	64
HLA‐B*35:01 and Green Tea–Induced Liver Injury	64
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis	64
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury	64
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable Features	64
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury	63
Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality	63
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity	62
IL‐6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	62
Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID‐19): U.S. Multicenter Experience	61
Evolution of Systemic Therapy for Hepatocellular Carcinoma	61
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors	60
The Emerging Role of B Cells in the Pathogenesis of NAFLD	60
Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study	60
Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management	60
Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study	60
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis	60
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma	59
Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome	59
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study	58
Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression	58
Liver Cancer Immunity	58
Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation	58
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling	57
Health disparities in chronic liver disease	57
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation	57
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis	57
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates	56
Monocytes as Potential Mediators of Pathogen‐Induced T‐Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC)	56
LSD1‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1‐Induced p62 Transcription in HCC	56
Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers	56
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients	56
Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α	56
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care	56
Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice	56
Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ Signaling	55
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma	55

Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell‐free DNA fragmentomics	55
Shear stress–induced cellular senescence blunts liver regeneration through Notch–sirtuin 1–P21/P16 axis	55
Endoscopic Cyanoacrylate Injection Versus Balloon‐Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial	54
Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension	54
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis	54
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes	53
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease	53
Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B	53
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD	53
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH	52
Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD	52
Microwave ablation versus laparoscopic resection as first‐line therapy for solitary 3–5‐cm HCC	52
PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity	52
DNA Methylation Profiling of Human Hepatocarcinogenesis	52
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis	52
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications	52
Mechanisms of drug resistance in HCC	52
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	52
Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice	52
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses	51
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	51
Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance	51
Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!	51
Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC	51
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs	51
Risk factors for HCC in contemporary cohorts of patients with cirrhosis	51
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy	51
Inflammation‐Induced Long Intergenic Noncoding RNA (LINC00665) Increases Malignancy Through Activating the Double‐Stranded RNA–Activated Protein Kinase/Nuclear Factor Kappa B Pathway in Hepatocellular	51
Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States	51
Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study	51
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH	50
HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3	50
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease	50
MiR‐125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma	50
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD	49
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis	49
NAFLD and Alcohol‐Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040	49
Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation	49
Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice	49
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study	49
Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population‐Based Study of 1,355 Adults	48
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis	48
YAP‐TEAD mediates PPAR α–induced hepatomegaly and liver regeneration in mice	48
DDX17‐regulated alternative splicing that produced an oncogenic isoform of PXN‐AS1 to promote HCC metastasis	48
Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies	48
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B	48
Two Faces of Neutrophils in Liver Disease Development and Progression	48
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial	47
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice	47
Diabetes medications and risk of HCC	47
Intratumoral γδ T‐Cell Infiltrates, Chemokine (C‐C Motif) Ligand 4/Chemokine (C‐C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma	47
Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis	47
L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial	47
European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children	47
Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	47
Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia	46
Geographical similarity and differences in the burden and genetic predisposition of NAFLD	46
An Endoplasmic Reticulum Stress–MicroRNA‐26a Feedback Circuit in NAFLD	46
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease	46
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors	46
The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis	46
Farnesoid X Receptor Activation Impairs Liver Progenitor Cell–Mediated Liver Regeneration via the PTEN‐PI3K‐AKT‐mTOR Axis in Zebrafish	46
Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling	46
Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant	46
Hepatocyte Nuclear Factor 4α Prevents the Steatosis‐to‐NASH Progression by Regulating p53 and Bile Acid Signaling (in mice)	46
Frailty is associated with increased risk of cirrhosis disease progression and death	46
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis	45
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	45
T‐Cell Immunoglobulin and Mucin Domain‐Containing Protein‐4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury	45
A strategy of vascular‐targeted therapy for liver fibrosis	45
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis	44
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases	44
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: A rare adverse effect?	44
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim‐Sulfamethoxazole Induced Liver Injury	43
Prevalence of HBV Infection, Vaccine‐Induced Immunity, and Susceptibility Among At‐Risk Populations: US Households, 2013‐2018	43
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis	43
H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen‐Activated Protein Kinase–Dependent Manner and Sponging micro	43
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19	43
Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications	42
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System	42
Therapeutic efficacy of FASN inhibition in preclinical models of HCC	42
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?	42
Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma	42
Gallstones, Body Mass Index, C‐Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data	41
Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)	41
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis	41
Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation	41
Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells	41
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression	41
Model for End‐Stage Liver Disease‐Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease	41
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial	40
Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer	40
Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex	40
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer‐Associated Fibroblasts Formed After Chronic Liver Injuries	40
Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions	40